查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1574759

硬纖維瘤市場：按藥物類型、治療類型、最終用戶、年齡層、腫瘤部位分類 - 全球預測 2025-2030

Desmoid Tumors Market by Drug Type (Anti-Hormonal Therapy, Chemotherapy, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)), Treatment Type (Cryoablation, Radiation Therapy, Surgery), End User, Age Group, Tumor Location - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

硬纖維瘤市場2023年估值為25.8億美元，預計2024年將達27.2億美元，複合年成長率為5.83%，到2030年將達到38.4億美元。

硬纖維瘤，也稱為侵襲性纖維瘤病，是罕見的非轉移性軟組織腫瘤，由結締組織產生並表現出浸潤性生長模式。了解硬纖維瘤的市場範圍需要認知到由於治療選擇有限且對患者生活品質產生重大影響而需要標靶治療。主要用途包括手術切除、荷爾蒙療法、非類固醇消炎劑(NSAID)、放射線治療以及最近使用的標靶藥物和化療。最終用戶包括專門從事腫瘤學和罕見疾病的醫院、診所和研究中心。影響市場的關鍵成長要素包括對硬纖維瘤認知和診斷的提高、分子生物學的進步導致了 CTNNB1 基因等基因突變的識別，以及針對特定分子標靶的新型療法的開發。

主要市場統計
基準年[2023] 25.8億美元
預測年份 [2024] 27.2億美元
預測年份 [2030] 38.4億美元
複合年成長率（%） 5.83%

潛在的市場機會在於增加對標靶治療和個人化醫療研發的投資。新分子療法和人工智慧主導的藥物發現平台的使用為技術創新提供了肥沃的土壤。此外，製藥公司對罕見疾病市場的興趣日益濃厚，為希望利用治療方案創新的新參與企業提供了充足的潛力。然而，該市場面臨諸如硬纖維瘤病理生理學的複雜性、影響盈利的患者群體有限以及研發成本高等限制。此外，克服孤兒藥的監管挑戰可能是一個主要瓶頸。

利用基因組定序的進步來開發個人化治療方法並最佳化非侵入性診斷技術是實現業務成長創新的最佳途徑。探索與學術機構和生物技術公司的合作夥伴關係可以釋放更多的研究見解並加速研發。硬纖維瘤市場的特點是醫療需求未滿足的利基市場很高，但隨著治療方法的發展變得更加有效和精確，該市場有望成長。為了取得成功，我們必須專注於策略聯盟，擴大全球意識計劃，並投資於突破性發現，以提高治療效果和市場滲透率。

市場動態：揭示快速發展的硬纖維瘤市場的關鍵市場洞察

供需的動態交互作用正在改變硬纖維瘤市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 加強診斷技術，實現早期發現並改善治療策略
    • 發展針對個別硬纖維瘤概況的個人化醫療方法
    • 越來越注重以病人為中心的照護和支援服務，以提高生活品質
    • 擴大臨床試驗招募範圍，為硬纖維瘤提供最先進治療
  • 市場限制因素
    • 意識下降與誤診
  • 市場機會
    • 利用人工智慧和機器學習進行硬纖維瘤的早期檢測和治療計劃
    • 製藥公司與研究機構合作，加速開發硬纖維瘤新治療方案
    • 加強公眾意識宣傳活動，並專注於硬纖維瘤的早期診斷和可用治療方案
  • 市場挑戰
    • 嚴格的核准和監管流程

波特的五力：駕馭硬纖維瘤市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解硬纖維瘤市場的外部影響

外部宏觀環境因素在塑造硬纖維瘤市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解硬纖維瘤市場的競爭格局

硬纖維瘤市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣硬纖維瘤市場供應商的績效評估

FPNV定位矩陣是評估硬纖維瘤市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製硬纖維瘤市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對硬纖維瘤市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 改進的診斷技術可以實現早期檢測並改進治療策略
      • 開發針對硬纖維瘤個別特徵的個人化醫療方法
      • 注重以病人為中心的照護和支援服務，提高生活品質
      • 擴大臨床試驗招募範圍並提供尖端的硬纖維瘤治療方法
    • 抑制因素
      • 缺乏認知與誤診
    • 機會
      • 利用人工智慧和機器學習進行硬纖維瘤的早期檢測和治療計劃
      • 製藥公司和研究機構合作加速新治療方法的開發
      • 加強宣傳宣傳活動，重點關注硬纖維瘤的早期診斷和可用治療方案
    • 任務
      • 嚴格的核准和監管流程
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類型分類的硬纖維瘤市場

  • 抗荷爾蒙荷爾蒙療法
  • 化療
  • 非類固醇消炎劑(NSAID)

第7章依治療類型分類的硬纖維瘤市場

  • 冷凍療法
  • 放射治療
  • 外科手術

第 8 章硬纖維瘤市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第9章硬纖維瘤市場：依年齡層

  • 成人用
  • 老年病
  • 小兒科

第10章依腫瘤部位分類的硬纖維瘤市場

  • 腹部
  • 腹部外
  • 腹膜內

第11章美洲硬纖維瘤市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區硬纖維瘤市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲的硬纖維瘤市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-535C629188EE

The Desmoid Tumors Market was valued at USD 2.58 billion in 2023, expected to reach USD 2.72 billion in 2024, and is projected to grow at a CAGR of 5.83%, to USD 3.84 billion by 2030.

Desmoid tumors, also known as aggressive fibromatosis, are rare, non-metastasizing soft tissue tumors that arise from the connective tissue and exhibit an infiltrative growth pattern. Understanding the market scope for desmoid tumors involves recognizing the necessity for targeted therapies, given the limited treatment options and significant impact on patient quality of life. Applications primarily include surgical resections, hormonal therapies, NSAIDs, radiation therapy, and more recently, the use of targeted agents and chemotherapy. End-users encompass hospitals, clinics, and research centers focused on oncology and rare diseases. Key growth factors influencing the market include increased awareness and diagnosis of desmoid tumors, advances in molecular biology that have led to the identification of genetic mutations like the CTNNB1 gene, and the ongoing development of novel therapeutics aimed at specific molecular targets.

KEY MARKET STATISTICS
Base Year [2023] USD 2.58 billion
Estimated Year [2024] USD 2.72 billion
Forecast Year [2030] USD 3.84 billion
CAGR (%) 5.83%

The market's potential opportunities lie in increasing investments in research and development for targeted therapies and personalized medicine. Emerging molecular therapies and the use of AI-driven drug discovery platforms present fertile grounds for innovation. Furthermore, the growing interest in rare disease markets by pharmaceutical companies provides ample potential for new entrants aiming to capitalize on innovation in treatment options. However, the market faces limitations such as the complex nature of desmoid tumor pathophysiology, limited patient populations that affect profitability and high R&D costs. Additionally, navigating regulatory challenges for orphan drugs can be a significant bottleneck.

For business growth, the best avenues of innovation include leveraging advancements in genomic sequencing to develop personalized treatment regimens and optimizing non-invasive diagnostic techniques. Exploring partnerships with academic institutions and biotech firms may unlock further research insights and speed up therapeutic development. The desmoid tumor market is characterized by its niche nature with high unmet medical needs but is poised for growth as treatments evolve to become more effective and precise. To thrive, businesses should focus on strategic alliances, expand global awareness programs, and invest in breakthrough discoveries to enhance therapeutic outcomes and market penetration.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Desmoid Tumors Market

The Desmoid Tumors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Enhanced diagnostic techniques leading to earlier detection and improved treatment strategies
    • Development of personalized medicine approaches tailored to individual desmoid tumor profiles
    • Elevated focus on patient-centric care and support services improving quality of life
    • Expanding clinical trial enrollments providing access to cutting-edge therapies for desmoid tumors
  • Market Restraints
    • Limited awareness and misdiagnosis
  • Market Opportunities
    • Utilization of artificial intelligence and machine learning for early detection and treatment planning in Desmoid tumors
    • Collaboration between pharmaceutical companies and research institutions to accelerate the development of new treatment options for Desmoid tumors
    • Enhanced public awareness campaigns focusing on early diagnosis and available treatment options for Desmoid tumors
  • Market Challenges
    • Stringent approval and regulatory process

Porter's Five Forces: A Strategic Tool for Navigating the Desmoid Tumors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Desmoid Tumors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Desmoid Tumors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Desmoid Tumors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Desmoid Tumors Market

A detailed market share analysis in the Desmoid Tumors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Desmoid Tumors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Desmoid Tumors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Desmoid Tumors Market

A strategic analysis of the Desmoid Tumors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Desmoid Tumors Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Amgen, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Incyte Corporation, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Roche, Sanofi, SpringWorks Therapeutics, Takeda Pharmaceutical, and Teva Pharmaceutical.

Market Segmentation & Coverage

This research report categorizes the Desmoid Tumors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Anti-Hormonal Therapy, Chemotherapy, and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
  • Based on Treatment Type, market is studied across Cryoablation, Radiation Therapy, and Surgery.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
  • Based on Age Group, market is studied across Adult, Geriatric, and Pediatric.
  • Based on Tumor Location, market is studied across Abdominal, Extra-Abdominal, and Intra-Abdominal.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Enhanced diagnostic techniques leading to earlier detection and improved treatment strategies
      • 5.1.1.2. Development of personalized medicine approaches tailored to individual desmoid tumor profiles
      • 5.1.1.3. Elevated focus on patient-centric care and support services improving quality of life
      • 5.1.1.4. Expanding clinical trial enrollments providing access to cutting-edge therapies for desmoid tumors
    • 5.1.2. Restraints
      • 5.1.2.1. Limited awareness and misdiagnosis
    • 5.1.3. Opportunities
      • 5.1.3.1. Utilization of artificial intelligence and machine learning for early detection and treatment planning in Desmoid tumors
      • 5.1.3.2. Collaboration between pharmaceutical companies and research institutions to accelerate the development of new treatment options for Desmoid tumors
      • 5.1.3.3. Enhanced public awareness campaigns focusing on early diagnosis and available treatment options for Desmoid tumors
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent approval and regulatory process
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Desmoid Tumors Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Anti-Hormonal Therapy
  • 6.3. Chemotherapy
  • 6.4. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

7. Desmoid Tumors Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Cryoablation
  • 7.3. Radiation Therapy
  • 7.4. Surgery

8. Desmoid Tumors Market, by End User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Desmoid Tumors Market, by Age Group

  • 9.1. Introduction
  • 9.2. Adult
  • 9.3. Geriatric
  • 9.4. Pediatric

10. Desmoid Tumors Market, by Tumor Location

  • 10.1. Introduction
  • 10.2. Abdominal
  • 10.3. Extra-Abdominal
  • 10.4. Intra-Abdominal

11. Americas Desmoid Tumors Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Desmoid Tumors Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Desmoid Tumors Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie
  • 2. Amgen
  • 3. AstraZeneca
  • 4. Bayer
  • 5. Blueprint Medicines
  • 6. Bristol-Myers Squibb
  • 7. Celgene Corporation
  • 8. Eli Lilly and Company
  • 9. Gilead Sciences
  • 10. GlaxoSmithKline
  • 11. Incyte Corporation
  • 12. Johnson & Johnson
  • 13. Merck & Co.
  • 14. Novartis
  • 15. Pfizer
  • 16. Roche
  • 17. Sanofi
  • 18. SpringWorks Therapeutics
  • 19. Takeda Pharmaceutical
  • 20. Teva Pharmaceutical

LIST OF FIGURES

  • FIGURE 1. DESMOID TUMORS MARKET RESEARCH PROCESS
  • FIGURE 2. DESMOID TUMORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DESMOID TUMORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DESMOID TUMORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DESMOID TUMORS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DESMOID TUMORS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES DESMOID TUMORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES DESMOID TUMORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. DESMOID TUMORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. DESMOID TUMORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DESMOID TUMORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DESMOID TUMORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DESMOID TUMORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DESMOID TUMORS MARKET DYNAMICS
  • TABLE 7. GLOBAL DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DESMOID TUMORS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DESMOID TUMORS MARKET SIZE, BY CRYOABLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DESMOID TUMORS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DESMOID TUMORS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DESMOID TUMORS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DESMOID TUMORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DESMOID TUMORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DESMOID TUMORS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DESMOID TUMORS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DESMOID TUMORS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DESMOID TUMORS MARKET SIZE, BY ABDOMINAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DESMOID TUMORS MARKET SIZE, BY EXTRA-ABDOMINAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DESMOID TUMORS MARKET SIZE, BY INTRA-ABDOMINAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES DESMOID TUMORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 236. DESMOID TUMORS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 237. DESMOID TUMORS MARKET, FPNV POSITIONING MATRIX, 2023